Twin epidemics: The surging rise of methamphetamine use in chronic opioid users

•Co-occurring opioid and methamphetamine use have doubled from 2011 to 2017.•Methamphetamine serves as an easily accessible and affordable substitute to opioids.•Co-occurring use provides synergistic effects whereby one balances out the other. Background/aims: Recent supply-side efforts enacted to c...

Full description

Saved in:
Bibliographic Details
Published inDrug and alcohol dependence Vol. 193; pp. 14 - 20
Main Authors Ellis, Matthew S., Kasper, Zachary A., Cicero, Theodore J.
Format Journal Article
LanguageEnglish
Published Ireland Elsevier B.V 01.12.2018
Elsevier Science Ltd
Subjects
Online AccessGet full text

Cover

Loading…
Abstract •Co-occurring opioid and methamphetamine use have doubled from 2011 to 2017.•Methamphetamine serves as an easily accessible and affordable substitute to opioids.•Co-occurring use provides synergistic effects whereby one balances out the other. Background/aims: Recent supply-side efforts enacted to curb the opioid epidemic have had both positive (i.e., prescription opioid abuse is on the decline) and negative outcomes (i.e., shifts to other drugs). Given methamphetamine is notably increasing in use across the United States, we sought to understand whether use of methamphetamine has increased among opioid users and whether there is an association between these two epidemics. Methods: Patients (N = 13,521) entering drug treatment programs across the United States completed an anonymous survey of drug use patterns from 2011 to 2017. A subset of these patients (N = 300) was also interviewed to add context and expand on the structured survey. Results: Past month use of methamphetamine significantly increased among treatment-seeking opioid users (+82.6%, p < .001), from 18.8% in 2011 to 34.2% in 2017. The Western region had the greatest increase in past month methamphetamine use (+202.4%, p < 0.001) and the highest prevalence rate in 2017 (63.0%). Significant increases (p < .001) in methamphetamine use were seen among males (+81.8%), females (+97.8%), whites (+100.6%), urban residents (+123.0%) and rural residents (+93.7%). Conclusions: Our studies show that there has been a marked increase in the past month use of methamphetamine in individuals with a primary indication of opioid use disorder. Qualitative data indicated that methamphetamine served as an opioid substitute, provided a synergistic high, and balanced out the effects of opioids so one could function “normally”. Our data suggest that, at least to some extent, efforts limiting access to prescription opioids may be associated with an increase in the use of methamphetamine.
AbstractList Recent supply-side efforts enacted to curb the opioid epidemic have had both positive (i.e., prescription opioid abuse is on the decline) and negative outcomes (i.e., shifts to other drugs). Given methamphetamine is notably increasing in use across the United States, we sought to understand whether use of methamphetamine has increased among opioid users and whether there is an association between these two epidemics. Patients (N = 13,521) entering drug treatment programs across the United States completed an anonymous survey of drug use patterns from 2011 to 2017. A subset of these patients (N = 300) was also interviewed to add context and expand on the structured survey. Past month use of methamphetamine significantly increased among treatment-seeking opioid users (+82.6%, p < .001), from 18.8% in 2011 to 34.2% in 2017. The Western region had the greatest increase in past month methamphetamine use (+202.4%, p < 0.001) and the highest prevalence rate in 2017 (63.0%). Significant increases (p < .001) in methamphetamine use were seen among males (+81.8%), females (+97.8%), whites (+100.6%), urban residents (+123.0%) and rural residents (+93.7%). Our studies show that there has been a marked increase in the past month use of methamphetamine in individuals with a primary indication of opioid use disorder. Qualitative data indicated that methamphetamine served as an opioid substitute, provided a synergistic high, and balanced out the effects of opioids so one could function "normally". Our data suggest that, at least to some extent, efforts limiting access to prescription opioids may be associated with an increase in the use of methamphetamine.
•Co-occurring opioid and methamphetamine use have doubled from 2011 to 2017.•Methamphetamine serves as an easily accessible and affordable substitute to opioids.•Co-occurring use provides synergistic effects whereby one balances out the other. Background/aims: Recent supply-side efforts enacted to curb the opioid epidemic have had both positive (i.e., prescription opioid abuse is on the decline) and negative outcomes (i.e., shifts to other drugs). Given methamphetamine is notably increasing in use across the United States, we sought to understand whether use of methamphetamine has increased among opioid users and whether there is an association between these two epidemics. Methods: Patients (N = 13,521) entering drug treatment programs across the United States completed an anonymous survey of drug use patterns from 2011 to 2017. A subset of these patients (N = 300) was also interviewed to add context and expand on the structured survey. Results: Past month use of methamphetamine significantly increased among treatment-seeking opioid users (+82.6%, p < .001), from 18.8% in 2011 to 34.2% in 2017. The Western region had the greatest increase in past month methamphetamine use (+202.4%, p < 0.001) and the highest prevalence rate in 2017 (63.0%). Significant increases (p < .001) in methamphetamine use were seen among males (+81.8%), females (+97.8%), whites (+100.6%), urban residents (+123.0%) and rural residents (+93.7%). Conclusions: Our studies show that there has been a marked increase in the past month use of methamphetamine in individuals with a primary indication of opioid use disorder. Qualitative data indicated that methamphetamine served as an opioid substitute, provided a synergistic high, and balanced out the effects of opioids so one could function “normally”. Our data suggest that, at least to some extent, efforts limiting access to prescription opioids may be associated with an increase in the use of methamphetamine.
Recent supply-side efforts enacted to curb the opioid epidemic have had both positive (i.e., prescription opioid abuse is on the decline) and negative outcomes (i.e., shifts to other drugs). Given methamphetamine is notably increasing in use across the United States, we sought to understand whether use of methamphetamine has increased among opioid users and whether there is an association between these two epidemics.BACKGROUND/AIMSRecent supply-side efforts enacted to curb the opioid epidemic have had both positive (i.e., prescription opioid abuse is on the decline) and negative outcomes (i.e., shifts to other drugs). Given methamphetamine is notably increasing in use across the United States, we sought to understand whether use of methamphetamine has increased among opioid users and whether there is an association between these two epidemics.Patients (N = 13,521) entering drug treatment programs across the United States completed an anonymous survey of drug use patterns from 2011 to 2017. A subset of these patients (N = 300) was also interviewed to add context and expand on the structured survey.METHODSPatients (N = 13,521) entering drug treatment programs across the United States completed an anonymous survey of drug use patterns from 2011 to 2017. A subset of these patients (N = 300) was also interviewed to add context and expand on the structured survey.Past month use of methamphetamine significantly increased among treatment-seeking opioid users (+82.6%, p < .001), from 18.8% in 2011 to 34.2% in 2017. The Western region had the greatest increase in past month methamphetamine use (+202.4%, p < 0.001) and the highest prevalence rate in 2017 (63.0%). Significant increases (p < .001) in methamphetamine use were seen among males (+81.8%), females (+97.8%), whites (+100.6%), urban residents (+123.0%) and rural residents (+93.7%).RESULTSPast month use of methamphetamine significantly increased among treatment-seeking opioid users (+82.6%, p < .001), from 18.8% in 2011 to 34.2% in 2017. The Western region had the greatest increase in past month methamphetamine use (+202.4%, p < 0.001) and the highest prevalence rate in 2017 (63.0%). Significant increases (p < .001) in methamphetamine use were seen among males (+81.8%), females (+97.8%), whites (+100.6%), urban residents (+123.0%) and rural residents (+93.7%).Our studies show that there has been a marked increase in the past month use of methamphetamine in individuals with a primary indication of opioid use disorder. Qualitative data indicated that methamphetamine served as an opioid substitute, provided a synergistic high, and balanced out the effects of opioids so one could function "normally". Our data suggest that, at least to some extent, efforts limiting access to prescription opioids may be associated with an increase in the use of methamphetamine.CONCLUSIONSOur studies show that there has been a marked increase in the past month use of methamphetamine in individuals with a primary indication of opioid use disorder. Qualitative data indicated that methamphetamine served as an opioid substitute, provided a synergistic high, and balanced out the effects of opioids so one could function "normally". Our data suggest that, at least to some extent, efforts limiting access to prescription opioids may be associated with an increase in the use of methamphetamine.
Background/aims: Recent supply-side efforts enacted to curb the opioid epidemic have had both positive (i.e., prescription opioid abuse is on the decline) and negative outcomes (i.e., shifts to other drugs). Given methamphetamine is notably increasing in use across the United States, we sought to understand whether use of methamphetamine has increased among opioid users and whether there is an association between these two epidemics. Methods: Patients (N = 13,521) entering drug treatment programs across the United States completed an anonymous survey of drug use patterns from 2011 to 2017. A subset of these patients (N = 300) was also interviewed to add context and expand on the structured survey. Results: Past month use of methamphetamine significantly increased among treatment-seeking opioid users (+82.6%, p < .001), from 18.8% in 2011 to 34.2% in 2017. The Western region had the greatest increase in past month methamphetamine use (+202.4%, p < 0.001) and the highest prevalence rate in 2017 (63.0%). Significant increases (p < .001) in methamphetamine use were seen among males (+81.8%), females (+97.8%), whites (+100.6%), urban residents (+123.0%) and rural residents (+93.7%). Conclusions: Our studies show that there has been a marked increase in the past month use of methamphetamine in individuals with a primary indication of opioid use disorder. Qualitative data indicated that methamphetamine served as an opioid substitute, provided a synergistic high, and balanced out the effects of opioids so one could function “normally”. Our data suggest that, at least to some extent, efforts limiting access to prescription opioids may be associated with an increase in the use of methamphetamine.
Author Kasper, Zachary A.
Cicero, Theodore J.
Ellis, Matthew S.
Author_xml – sequence: 1
  givenname: Matthew S.
  surname: Ellis
  fullname: Ellis, Matthew S.
  email: ellism@wustl.edu
– sequence: 2
  givenname: Zachary A.
  surname: Kasper
  fullname: Kasper, Zachary A.
– sequence: 3
  givenname: Theodore J.
  surname: Cicero
  fullname: Cicero, Theodore J.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30326396$$D View this record in MEDLINE/PubMed
BookMark eNqNkU1v1DAQhi1URLeFv4AiceGSxR9Zx-aAgIoWpEq9LGfLcSa7syR2sBNQ_z2OthXSntYaydL4mXfG816RCx88EFIwumaUyQ-HdRvnne1dC-OaU6bWNAfXL8iKqVqXlFbygqyoqGWpaiYvyVVKB5qP1PQVuRRUcCm0XJGH7V_0BYzYwoAufSy2eyjSHHfod0XEBEXoigGmvR3GPUx2QA_FnNO5yu1j8OiKMGLAdsnG9Jq87Gyf4M3TfU1-3n7b3nwv7x_uftx8uS9dtdFT2WwqyhuoVMNsS52kTOeBmMqPzLqm0g2wTljQlAu1oYqpRje1kh3UFa9Ai2vy_qg7xvB7hjSZAZODvrcewpwMZ5xV-eucZfTdCXoIc_R5ukxt6qoWTCzU2ydqbgZozRhxsPHRPK8qA5-OgIshpQidcTjZCYOfosXeMGoWb8zB_PfGLN4YmoMvI6sTgeceZ5R-PZZCXukfhGiSQ_AOWozgJtMGPEfk84mI6zH7Z_tf8HiexD_1G8PW
CitedBy_id crossref_primary_10_1111_dar_13918
crossref_primary_10_1136_openhrt_2021_001930
crossref_primary_10_1001_jamanetworkopen_2023_41921
crossref_primary_10_1080_10826084_2021_2003404
crossref_primary_10_1016_j_drugalcdep_2022_109341
crossref_primary_10_1016_j_drugalcdep_2022_109469
crossref_primary_10_1016_j_dadr_2023_100163
crossref_primary_10_31389_jied_122
crossref_primary_10_1111_add_16760
crossref_primary_10_1016_j_mcna_2023_06_017
crossref_primary_10_1016_j_drugpo_2022_103584
crossref_primary_10_1016_j_drugpo_2023_104150
crossref_primary_10_1186_s13722_021_00267_1
crossref_primary_10_3389_fpsyt_2021_784229
crossref_primary_10_3390_v12111297
crossref_primary_10_1371_journal_pone_0245920
crossref_primary_10_1080_15563650_2020_1853143
crossref_primary_10_2105_AJPH_2020_305748
crossref_primary_10_1007_s11121_021_01215_w
crossref_primary_10_1016_j_jsat_2020_01_010
crossref_primary_10_1177_0022042620959071
crossref_primary_10_3389_fnins_2020_00569
crossref_primary_10_1371_journal_pmed_1002969
crossref_primary_10_1080_14737167_2024_2350561
crossref_primary_10_1186_s13011_021_00350_5
crossref_primary_10_1186_s13722_022_00322_5
crossref_primary_10_1016_j_jsat_2021_108461
crossref_primary_10_1016_j_neubiorev_2022_104714
crossref_primary_10_1007_s10461_022_03605_9
crossref_primary_10_1146_annurev_pharmtox_030220_124205
crossref_primary_10_1093_aje_kwab290
crossref_primary_10_1016_j_drugalcdep_2024_111098
crossref_primary_10_1093_sleep_zsab001
crossref_primary_10_1001_jamanetworkopen_2022_11641
crossref_primary_10_1186_s12954_023_00816_8
crossref_primary_10_1186_s12954_024_00928_9
crossref_primary_10_1016_j_jcrimjus_2024_102167
crossref_primary_10_1016_j_drugalcdep_2021_108750
crossref_primary_10_1016_j_cppeds_2022_101265
crossref_primary_10_1016_j_drugalcdep_2020_108357
crossref_primary_10_1111_dar_13261
crossref_primary_10_1111_1556_4029_15373
crossref_primary_10_1016_j_ajem_2023_01_042
crossref_primary_10_1111_jrh_12743
crossref_primary_10_1097_ADM_0000000000000824
crossref_primary_10_1186_s13722_021_00266_2
crossref_primary_10_1016_j_josat_2023_208956
crossref_primary_10_1186_s12954_022_00721_6
crossref_primary_10_1016_j_apnu_2024_07_007
crossref_primary_10_1016_j_amepre_2024_10_012
crossref_primary_10_1016_j_pmedr_2023_102494
crossref_primary_10_1186_s12889_022_14506_w
crossref_primary_10_3389_fpsyt_2021_805002
crossref_primary_10_1186_s12889_022_12678_z
crossref_primary_10_1192_bjp_2023_111
crossref_primary_10_1016_j_drugalcdep_2021_108767
crossref_primary_10_1016_j_drugalcdep_2021_108527
crossref_primary_10_1016_j_josat_2023_209012
crossref_primary_10_1177_07067437221125302
crossref_primary_10_1080_00952990_2021_1981919
crossref_primary_10_1001_jamanetworkopen_2022_11634
crossref_primary_10_1016_j_ypmed_2021_106729
crossref_primary_10_2147_NDT_S331442
crossref_primary_10_1097_JAN_0000000000000298
crossref_primary_10_2196_45717
crossref_primary_10_1016_j_jsat_2022_108830
crossref_primary_10_1080_10826084_2021_1975747
crossref_primary_10_1016_j_drugalcdep_2021_109145
crossref_primary_10_1016_j_drugalcdep_2019_01_045
crossref_primary_10_1016_j_drugalcdep_2020_108333
crossref_primary_10_1111_ajad_13619
crossref_primary_10_1007_s13181_022_00924_0
crossref_primary_10_1159_000519541
crossref_primary_10_1124_jpet_119_258699
crossref_primary_10_1080_14659891_2022_2157770
crossref_primary_10_2105_AJPH_2021_306373
crossref_primary_10_1097_ADM_0000000000000726
crossref_primary_10_1016_j_abrep_2021_100353
crossref_primary_10_3389_fgene_2022_837123
crossref_primary_10_1016_j_jsat_2021_108666
crossref_primary_10_1016_j_drugalcdep_2019_107592
crossref_primary_10_1016_j_nicl_2019_102068
crossref_primary_10_3389_fphar_2022_859563
crossref_primary_10_1080_02791072_2025_2478090
crossref_primary_10_1016_j_drugalcdep_2022_109535
crossref_primary_10_1016_j_drugalcdep_2020_108323
crossref_primary_10_1111_dar_13690
crossref_primary_10_1016_j_jstrokecerebrovasdis_2024_108178
crossref_primary_10_1097_ADM_0000000000000611
crossref_primary_10_1186_s12954_024_00976_1
crossref_primary_10_1016_j_drugpo_2020_103098
crossref_primary_10_1080_15563650_2024_2391011
crossref_primary_10_3390_ijerph192416759
crossref_primary_10_1111_add_16147
crossref_primary_10_1186_s13063_021_05919_w
crossref_primary_10_1186_s13722_023_00402_0
crossref_primary_10_3390_ijerph182111072
crossref_primary_10_1016_j_addbeh_2020_106379
crossref_primary_10_1016_j_josat_2024_209614
crossref_primary_10_1080_10826084_2020_1765805
crossref_primary_10_1097_ADM_0000000000001035
crossref_primary_10_1891_JDNP_2023_0019
crossref_primary_10_1016_j_drugalcdep_2023_110956
crossref_primary_10_1177_29768357241272374
crossref_primary_10_1111_adb_12831
crossref_primary_10_1080_10826084_2021_1963987
crossref_primary_10_1016_j_drugalcdep_2021_108719
crossref_primary_10_1186_s13011_021_00414_6
crossref_primary_10_2196_48405
crossref_primary_10_1186_s12889_021_11783_9
crossref_primary_10_1097_MLR_0000000000001460
crossref_primary_10_3389_fpsyt_2021_804997
crossref_primary_10_1093_infdis_jiaa129
crossref_primary_10_1093_epirev_mxaa011
crossref_primary_10_3390_ijerph19042230
crossref_primary_10_1016_j_ypmed_2020_106194
crossref_primary_10_1097_CXA_0000000000000068
crossref_primary_10_1016_j_drugalcdep_2021_109256
crossref_primary_10_1093_infdis_jiaa005
crossref_primary_10_1016_j_drugalcdep_2021_108844
crossref_primary_10_1016_j_abrep_2020_100289
crossref_primary_10_1080_10550887_2021_2005382
crossref_primary_10_1186_s13722_023_00364_3
crossref_primary_10_1001_jamapsychiatry_2021_2588
crossref_primary_10_1177_10249079231179103
crossref_primary_10_1097_ADM_0000000000000876
crossref_primary_10_1097_ADT_0000000000000253
crossref_primary_10_3389_fsoc_2020_593925
crossref_primary_10_1007_s00127_023_02500_5
crossref_primary_10_1007_s11469_023_01134_7
crossref_primary_10_1080_23279095_2022_2164197
crossref_primary_10_1016_j_drugpo_2022_103592
crossref_primary_10_1007_s00213_019_05399_6
crossref_primary_10_1016_j_drugalcdep_2025_112630
crossref_primary_10_1111_nyas_14688
crossref_primary_10_1111_add_15954
crossref_primary_10_1016_j_drugalcdep_2022_109740
crossref_primary_10_1001_jamanetworkopen_2024_41063
crossref_primary_10_1002_jaba_2911
crossref_primary_10_1016_j_josat_2023_209079
crossref_primary_10_1177_07067437231158933
crossref_primary_10_1080_14659891_2020_1738573
crossref_primary_10_1016_j_drugpo_2021_103463
crossref_primary_10_1080_10826084_2023_2287220
crossref_primary_10_1016_j_josat_2024_209365
crossref_primary_10_1016_j_drugalcdep_2020_108416
crossref_primary_10_1176_appi_prcp_20240051
crossref_primary_10_1111_add_15714
crossref_primary_10_1016_j_drugalcdep_2024_111133
crossref_primary_10_1186_s12916_024_03646_y
crossref_primary_10_1016_j_saa_2024_125234
crossref_primary_10_1177_00220426241231720
crossref_primary_10_1186_s13011_022_00470_6
crossref_primary_10_1016_j_drugalcdep_2020_108084
crossref_primary_10_1111_add_14755
crossref_primary_10_3389_fpsyt_2022_918197
crossref_primary_10_1007_s11469_023_01098_8
crossref_primary_10_1080_02791072_2021_2006374
crossref_primary_10_1007_s40429_025_00625_y
crossref_primary_10_1016_j_drugalcdep_2021_108702
crossref_primary_10_1136_bmjopen_2021_059898
crossref_primary_10_1080_07359683_2024_2380118
crossref_primary_10_1080_08897077_2021_1946892
crossref_primary_10_1080_13218719_2023_2206870
crossref_primary_10_1016_j_addicn_2025_100204
crossref_primary_10_1186_s12954_024_00986_z
crossref_primary_10_1186_s13011_022_00504_z
crossref_primary_10_15585_mmwr_mm6834a2
crossref_primary_10_1108_IJOPH_12_2023_0084
crossref_primary_10_1080_03007995_2024_2333429
crossref_primary_10_7759_cureus_36468
crossref_primary_10_1016_j_drugalcdep_2020_108193
crossref_primary_10_1080_15332640_2022_2109790
crossref_primary_10_1016_j_mcna_2021_08_010
crossref_primary_10_1136_bmjopen_2021_060447
crossref_primary_10_1016_j_drugalcdep_2023_110911
crossref_primary_10_3389_fpsyg_2021_689483
crossref_primary_10_1097_ADM_0000000000000667
crossref_primary_10_1097_ADM_0000000000000669
crossref_primary_10_1371_journal_pone_0252090
crossref_primary_10_1016_j_drugalcdep_2019_107574
crossref_primary_10_1016_j_josat_2022_208934
crossref_primary_10_1186_s12905_020_01088_1
crossref_primary_10_1097_ADM_0000000000001095
crossref_primary_10_1186_s12954_022_00630_8
crossref_primary_10_1093_ofid_ofac708
crossref_primary_10_1080_17512433_2023_2279192
crossref_primary_10_1080_14659891_2024_2423616
crossref_primary_10_1007_s10461_021_03381_y
crossref_primary_10_3389_fpsyt_2020_00750
crossref_primary_10_1080_16066359_2023_2167982
crossref_primary_10_1007_s11121_023_01602_5
crossref_primary_10_3389_fpsyt_2021_786056
crossref_primary_10_1186_s12954_021_00500_9
crossref_primary_10_1016_j_amepre_2023_10_002
crossref_primary_10_1097_AOG_0000000000003907
crossref_primary_10_1093_infdis_jiz445
crossref_primary_10_1080_10826084_2021_1949612
crossref_primary_10_1016_j_addbeh_2020_106752
crossref_primary_10_1016_j_josat_2023_208982
crossref_primary_10_1016_j_nurpra_2021_02_011
crossref_primary_10_1111_dar_13955
crossref_primary_10_1016_j_socscimed_2025_117843
crossref_primary_10_1080_14659891_2020_1808724
crossref_primary_10_1016_j_josat_2025_209685
crossref_primary_10_1186_s12879_020_05464_y
crossref_primary_10_1016_j_bcp_2024_116189
crossref_primary_10_1001_jamanetworkopen_2022_43653
crossref_primary_10_3390_ijms231710092
crossref_primary_10_1007_s11469_024_01378_x
crossref_primary_10_1111_add_16334
crossref_primary_10_1177_00220426241277763
crossref_primary_10_3389_fpsyt_2022_824940
crossref_primary_10_1093_cid_ciaa064
crossref_primary_10_1177_11782218231180043
crossref_primary_10_3390_ijms231911224
crossref_primary_10_3389_fpsyt_2022_835816
crossref_primary_10_1056_NEJMoa2020214
crossref_primary_10_1186_s12954_023_00782_1
crossref_primary_10_3390_ijerph20010543
crossref_primary_10_1177_00027162231154348
crossref_primary_10_1097_ADM_0000000000000695
crossref_primary_10_62401_2531_4122_2024_24
crossref_primary_10_1007_s10461_021_03460_0
crossref_primary_10_1080_1533256X_2023_2294287
crossref_primary_10_1080_15563650_2022_2038793
crossref_primary_10_2196_21212
crossref_primary_10_1186_s12889_020_09856_2
crossref_primary_10_1016_j_jpsychires_2023_05_018
crossref_primary_10_1186_s13063_022_06278_w
crossref_primary_10_1016_j_jsat_2022_108894
crossref_primary_10_1177_26334895211005809
crossref_primary_10_1371_journal_pone_0242165
crossref_primary_10_1186_s13722_023_00382_1
crossref_primary_10_1016_j_drugpo_2022_103879
crossref_primary_10_1097_CXA_0000000000000211
crossref_primary_10_3389_fpubh_2024_1279477
crossref_primary_10_1016_j_annemergmed_2020_06_046
crossref_primary_10_1016_j_bbr_2022_113876
crossref_primary_10_3390_vaccines10091508
crossref_primary_10_1177_08897077231199572
crossref_primary_10_1001_jamapsychiatry_2020_0246
crossref_primary_10_1186_s12954_022_00588_7
crossref_primary_10_1016_j_drugalcdep_2022_109274
crossref_primary_10_1177_02537176241236899
crossref_primary_10_1016_j_josat_2024_209589
crossref_primary_10_1016_j_drugalcdep_2020_108261
crossref_primary_10_1111_dar_13863
crossref_primary_10_1177_0022042619895247
crossref_primary_10_1016_j_drugalcdep_2020_108384
crossref_primary_10_1186_s13033_021_00512_9
crossref_primary_10_2105_AJPH_2019_305527
crossref_primary_10_1177_21501319231161208
crossref_primary_10_2105_AJPH_2019_305412
crossref_primary_10_1016_j_drugpo_2023_104103
crossref_primary_10_1111_add_14812
crossref_primary_10_1016_j_drugpo_2023_104222
crossref_primary_10_1186_s12954_024_01129_0
Cites_doi 10.1056/NEJMsa1406143
10.1111/j.1465-3362.2011.00291.x
10.15585/mmwr.mm6626a4
10.1016/j.neuroscience.2016.01.043
10.1056/NEJMra1508490
10.1016/j.emc.2015.11.002
10.1056/NEJMp1512932
10.15585/mmwr.mm6712a1
10.1016/j.brainresbull.2017.06.008
10.1177/003335491412900207
10.1016/j.drugalcdep.2016.03.014
10.1016/j.ajp.2018.02.004
10.1021/jacs.7b03334
10.15252/embr.201745322
10.15585/mmwr.mm6643e1
10.1016/j.jsat.2014.08.004
10.1213/ANE.0000000000002403
10.1080/15332640.2015.1070392
10.1111/j.1526-4637.2006.00259.x
10.1001/jamapsychiatry.2014.366
10.1001/jamapsychiatry.2014.3043
10.15288/jsad.2016.77.774
ContentType Journal Article
Copyright 2018 Elsevier B.V.
Copyright © 2018 Elsevier B.V. All rights reserved.
Copyright Elsevier Science Ltd. Dec 1, 2018
Copyright_xml – notice: 2018 Elsevier B.V.
– notice: Copyright © 2018 Elsevier B.V. All rights reserved.
– notice: Copyright Elsevier Science Ltd. Dec 1, 2018
DBID AAYXX
CITATION
NPM
7QJ
7TK
7U7
C1K
K9.
NAPCQ
7X8
DOI 10.1016/j.drugalcdep.2018.08.029
DatabaseName CrossRef
PubMed
Applied Social Sciences Index & Abstracts (ASSIA)
Neurosciences Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Toxicology Abstracts
Applied Social Sciences Index and Abstracts (ASSIA)
Neurosciences Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList PubMed

MEDLINE - Academic

ProQuest Health & Medical Complete (Alumni)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Social Welfare & Social Work
EISSN 1879-0046
EndPage 20
ExternalDocumentID 30326396
10_1016_j_drugalcdep_2018_08_029
S0376871618306872
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
1B1
1P~
1RT
1~.
1~5
4.4
457
4G.
5GY
5RE
5VS
6PF
7-5
71M
8P~
9JM
9JO
AABNK
AAEDT
AAEDW
AAFJI
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AATTM
AAWTL
AAXKI
AAXLA
AAXUO
ABBQC
ABCQJ
ABFNM
ABIVO
ABJNI
ABLJU
ABMAC
ABMMH
ABMZM
ABZDS
ACDAQ
ACGFS
ACHQT
ACIEU
ACIUM
ACPRK
ACRLP
ACVFH
ADBBV
ADCNI
ADEZE
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFPUW
AFRAH
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGUBO
AGWIK
AGYEJ
AHHHB
AIEXJ
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
AOMHK
APXCP
AVARZ
AXJTR
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
IHE
J1W
KOM
M29
M39
M41
MO0
MOBAO
N9A
O-L
O9-
OAUVE
OGGZJ
OH0
OU-
OZT
P-8
P-9
P2P
PC.
PRBVW
Q38
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SPCBC
SSB
SSH
SSN
SSO
SSP
SSZ
T5K
TN5
WH7
Z5R
~G-
AACTN
AADPK
AAIAV
AATCM
ABLVK
ABYKQ
AFKWA
AJOXV
AKYCK
AMFUW
EFLBG
LCYCR
RIG
.GJ
29G
53G
AAQXK
AAYWO
AAYXX
ABWVN
ABXDB
ACRPL
ADMUD
ADNMO
ADVLN
AFCTW
AFJKZ
AGQPQ
AGRNS
AIGII
ASPBG
AVWKF
AZFZN
CITATION
FEDTE
FGOYB
G-2
HEG
HMK
HMO
HVGLF
HZ~
H~9
R2-
SEW
UAP
WUQ
XPP
ZGI
ZXP
ZY4
NPM
7QJ
7TK
7U7
C1K
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c459t-b5402be48b1ad0c6019263184591acb49be1f3ae9023850818b9b786fe7424e93
IEDL.DBID .~1
ISSN 0376-8716
1879-0046
IngestDate Wed Jul 30 11:16:30 EDT 2025
Wed Aug 13 06:14:35 EDT 2025
Thu Apr 03 07:04:46 EDT 2025
Tue Jul 01 01:53:29 EDT 2025
Thu Apr 24 23:04:35 EDT 2025
Fri Feb 23 02:24:25 EST 2024
Tue Aug 26 20:29:13 EDT 2025
IsPeerReviewed true
IsScholarly true
Keywords Polysubstance use
Methamphetamine
Opioids
Language English
License Copyright © 2018 Elsevier B.V. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c459t-b5402be48b1ad0c6019263184591acb49be1f3ae9023850818b9b786fe7424e93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 30326396
PQID 2157473131
PQPubID 2033333
PageCount 7
ParticipantIDs proquest_miscellaneous_2121487121
proquest_journals_2157473131
pubmed_primary_30326396
crossref_citationtrail_10_1016_j_drugalcdep_2018_08_029
crossref_primary_10_1016_j_drugalcdep_2018_08_029
elsevier_sciencedirect_doi_10_1016_j_drugalcdep_2018_08_029
elsevier_clinicalkey_doi_10_1016_j_drugalcdep_2018_08_029
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-12-01
2018-12-00
20181201
PublicationDateYYYYMMDD 2018-12-01
PublicationDate_xml – month: 12
  year: 2018
  text: 2018-12-01
  day: 01
PublicationDecade 2010
PublicationPlace Ireland
PublicationPlace_xml – name: Ireland
– name: Lausanne
PublicationTitle Drug and alcohol dependence
PublicationTitleAlternate Drug Alcohol Depend
PublicationYear 2018
Publisher Elsevier B.V
Elsevier Science Ltd
Publisher_xml – name: Elsevier B.V
– name: Elsevier Science Ltd
References International Narcotics Control Board (bib0075) 2009
U.S. Customs and Border Protection (bib0150) 2018
Cicero, Ellis (bib0030) 2015; 72
Brady, Wunsch, DiMaggio, Lang, Giglio, Li (bib0010) 2014; 129
Meacham, Strathdee, Rangel, Armenta, Gaines, Garfein (bib0105) 2016; 77
Cicero, Ellis, Surratt, Kurtz (bib0040) 2014; 71
Mori, Iwase, Saeki, Iwata, Murata, Masukawa, Suzuki (bib0115) 2016; 322
Robles (bib0135) 2018
Soelberg, Brown, Du Vivier, Meyer, Ramachandran (bib0145) 2017; 125
Dart, Surratt, Cicero, Parrino, Severtson, Bucher-Bartelson, Green (bib0060) 2015; 372
Alford (bib0005) 2016; 374
Center for Substance Abuse Treatment (bib0025) 2004
McHugh, Nielsen, Weiss (bib0100) 2015; 48
Compton, Jones, Baldwin (bib0050) 2016; 374
U.S. Department of Justice, Drug Enforcement Administration (bib0155) 2017
Center for Behavioral Health Statistics and Quality (bib0020) 2015
Kuppili, Manohar, Menon (bib0080) 2018; 31
Dart, Surratt, Cicero, Parrino, Severtson, Bucher-Bartelson, Green (bib0055) 2015; 372
Seth, Scholl, Rudd, Bacon (bib0140) 2018; 67
Guy, Zhang, Bohm, Losby, Lewis, Young, Murphy, Dowell (bib0070) 2017; 66
DuPont (bib0065) 2018; 138
National Institute on Drug Abuse (bib0120) 2018
Maxwell (bib0095) 2011; 30
Montemayor (bib0110) 2018
Cicero, Ellis, Kasper (bib0045) 2017; 173
Lipari, Williams, Van Horn (bib0085) 2017
O’Donnell, Halpin, Mattson, Goldberger, Gladden (bib0125) 2017; 66
Olson, Janda (bib0130) 2018; 19
Bremer, Schlosburg, Banks, Steele, Zhou, Poklis, Janda (bib0015) 2017; 139
Cicero, Dart, Indiardi, Woody, Schnoll, Munoz (bib0035) 2007; 8
Wilkerson, Kim, Windsor, Mareiniss (bib0160) 2016; 34
Loza, Ramos, Ferreira-Pinto, Hernandez, Villalobos (bib0090) 2016; 15
McHugh (10.1016/j.drugalcdep.2018.08.029_bib0100) 2015; 48
Cicero (10.1016/j.drugalcdep.2018.08.029_bib0035) 2007; 8
Maxwell (10.1016/j.drugalcdep.2018.08.029_bib0095) 2011; 30
O’Donnell (10.1016/j.drugalcdep.2018.08.029_bib0125) 2017; 66
Mori (10.1016/j.drugalcdep.2018.08.029_bib0115) 2016; 322
International Narcotics Control Board (10.1016/j.drugalcdep.2018.08.029_bib0075) 2009
Seth (10.1016/j.drugalcdep.2018.08.029_bib0140) 2018; 67
Cicero (10.1016/j.drugalcdep.2018.08.029_bib0040) 2014; 71
Dart (10.1016/j.drugalcdep.2018.08.029_bib0055) 2015; 372
Soelberg (10.1016/j.drugalcdep.2018.08.029_bib0145) 2017; 125
Bremer (10.1016/j.drugalcdep.2018.08.029_bib0015) 2017; 139
Lipari (10.1016/j.drugalcdep.2018.08.029_bib0085) 2017
U.S. Customs and Border Protection (10.1016/j.drugalcdep.2018.08.029_bib0150) 2018
Compton (10.1016/j.drugalcdep.2018.08.029_bib0050) 2016; 374
Kuppili (10.1016/j.drugalcdep.2018.08.029_bib0080) 2018; 31
Loza (10.1016/j.drugalcdep.2018.08.029_bib0090) 2016; 15
Alford (10.1016/j.drugalcdep.2018.08.029_bib0005) 2016; 374
Brady (10.1016/j.drugalcdep.2018.08.029_bib0010) 2014; 129
Meacham (10.1016/j.drugalcdep.2018.08.029_bib0105) 2016; 77
Guy (10.1016/j.drugalcdep.2018.08.029_bib0070) 2017; 66
Olson (10.1016/j.drugalcdep.2018.08.029_bib0130) 2018; 19
Robles (10.1016/j.drugalcdep.2018.08.029_bib0135) 2018
Montemayor (10.1016/j.drugalcdep.2018.08.029_bib0110) 2018
U.S. Department of Justice, Drug Enforcement Administration (10.1016/j.drugalcdep.2018.08.029_bib0155) 2017
National Institute on Drug Abuse (10.1016/j.drugalcdep.2018.08.029_bib0120) 2018
Cicero (10.1016/j.drugalcdep.2018.08.029_bib0030) 2015; 72
Center for Behavioral Health Statistics and Quality (10.1016/j.drugalcdep.2018.08.029_bib0020) 2015
Cicero (10.1016/j.drugalcdep.2018.08.029_bib0045) 2017; 173
DuPont (10.1016/j.drugalcdep.2018.08.029_bib0065) 2018; 138
Wilkerson (10.1016/j.drugalcdep.2018.08.029_bib0160) 2016; 34
Center for Substance Abuse Treatment (10.1016/j.drugalcdep.2018.08.029_bib0025) 2004
Dart (10.1016/j.drugalcdep.2018.08.029_bib0060) 2015; 372
References_xml – volume: 374
  start-page: 154
  year: 2016
  end-page: 163
  ident: bib0050
  article-title: Relationship between nonmedical prescription-opioid use and heroin use
  publication-title: N. Engl. J. Med.
– volume: 48
  start-page: 1
  year: 2015
  end-page: 7
  ident: bib0100
  article-title: Prescription drug abuse: from epidemiology to public policy
  publication-title: J. Subst. Abuse Treat.
– volume: 19
  start-page: 5
  year: 2018
  end-page: 9
  ident: bib0130
  article-title: Vaccines to combat the opioid crisis. Vaccines that prevent opioids and other substances of abuse from entering the brain could effectively treat addiction and abuse
  publication-title: EMBO Rep.
– year: 2018
  ident: bib0110
  article-title: In the Shadow of the Opioid Crisis, Meth Has Roared Back into Minnesota
– volume: 72
  start-page: 424
  year: 2015
  end-page: 430
  ident: bib0030
  article-title: Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin
  publication-title: JAMA Psychiatry
– year: 2018
  ident: bib0120
  article-title: National Survey of Drug Use and Health: Trends in Prevalence of Various Drugs from Ages 12 or Older, Ages 12 to 17, Ages 18 to 25, and Ages 26 or Older; 2015–2016
– volume: 322
  start-page: 164
  year: 2016
  end-page: 170
  ident: bib0115
  article-title: Differential activation of dopaminergic systems in rat brain basal ganglia by morphine and methamphetamine
  publication-title: Neuroscience
– volume: 173
  start-page: S4
  year: 2017
  end-page: S10
  ident: bib0045
  article-title: Understanding the demand side of the prescription opioid epidemic: does the initial source of opioids matter?
  publication-title: Drug Alcohol Depend.
– volume: 138
  start-page: 112
  year: 2018
  end-page: 114
  ident: bib0065
  article-title: The opioid epidemic is an historic opportunity to improve both prevention and treatment
  publication-title: Brain Res. Bull.
– year: 2017
  ident: bib0155
  article-title: 2017 National Drug Threat Assessment. DEA-DCT-DIR-040-17
– volume: 372
  start-page: 241
  year: 2015
  end-page: 248
  ident: bib0055
  article-title: Trends in opioid analgesic abuse and mortality in the United States
  publication-title: N. Engl. J. Med.
– year: 2018
  ident: bib0135
  article-title: Meth, the Forgotten Killer, is Back. And It’s Everywhere
– year: 2015
  ident: bib0020
  article-title: Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. HHS Publication No. SMA 15-4927, NSDUH Series H-50
– year: 2009
  ident: bib0075
  article-title: Report of the International Narcotics Control Board for 2008
– volume: 34
  start-page: e1
  year: 2016
  end-page: e23
  ident: bib0160
  article-title: The opioid epidemic in the United States
  publication-title: Emerg. Med. Clin. North Am.
– volume: 30
  start-page: 264
  year: 2011
  end-page: 270
  ident: bib0095
  article-title: The prescription drug epidemic in the United States: a perfect storm
  publication-title: Drug Alcohol Rev.
– year: 2017
  ident: bib0085
  article-title: Why Do Adults Misuse Prescription Drugs? The CBHSQ Report
– volume: 66
  start-page: 1197
  year: 2017
  end-page: 1202
  ident: bib0125
  article-title: Deaths involving fentanyl, fentanyl analogs, and U-47700-10 States, July–December 2016
  publication-title: MMWR Morb. Mortal. Wkly. Rep.
– volume: 125
  start-page: 1675
  year: 2017
  end-page: 1681
  ident: bib0145
  article-title: The US opioid crisis: current federal and state legal issues
  publication-title: Anesth. Analg.
– volume: 77
  start-page: 774
  year: 2016
  end-page: 781
  ident: bib0105
  article-title: Prevalence and correlates of heroin-methamphetamine co-injection among persons who inject drugs in San Diego, California, and Tijuana, Baja California, Mexico
  publication-title: J. Stud. Alcohol Drugs
– year: 2018
  ident: bib0150
  article-title: CBP Enforcement Statistics FY
– volume: 139
  start-page: 8601
  year: 2017
  end-page: 8611
  ident: bib0015
  article-title: Development of a clinically viable heroin vaccine
  publication-title: J. Am. Chem. Soc.
– volume: 67
  start-page: 349
  year: 2018
  end-page: 358
  ident: bib0140
  article-title: Overdose deaths involving opioids, cocaine, and psychostimulants – United States, 2015–2016
  publication-title: MMWR Morb. Mortal. Wkly. Rep.
– year: 2004
  ident: bib0025
  article-title: Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction
  publication-title: Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration
– volume: 66
  start-page: 697
  year: 2017
  end-page: 704
  ident: bib0070
  article-title: Vital signs: changes in opioid prescribing in the United States, 2006–2015
  publication-title: MMWR Morb. Mortal. Wkly. Rep.
– volume: 374
  start-page: 301
  year: 2016
  end-page: 303
  ident: bib0005
  article-title: Opioid prescribing for chronic pain—achieving the right balance through education
  publication-title: N. Engl. J. Med.
– volume: 372
  start-page: 241
  year: 2015
  end-page: 248
  ident: bib0060
  article-title: Supplementary Appendix: trends in opioid analgesic abuse and mortality in the United States
  publication-title: N. Eng. J. Med.
– volume: 8
  start-page: 157
  year: 2007
  end-page: 170
  ident: bib0035
  article-title: The development of a comprehensive risk-management program for prescription opioid analgesics: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS
  publication-title: Pain Med.
– volume: 129
  start-page: 139
  year: 2014
  end-page: 147
  ident: bib0010
  article-title: Prescription drug monitoring and dispensing of prescription opioids
  publication-title: Public Health Rep.
– volume: 31
  start-page: 112
  year: 2018
  end-page: 120
  ident: bib0080
  article-title: Current state of vaccines in psychiatry—a narrative review
  publication-title: Asian J. Psychiatry
– volume: 15
  start-page: 405
  year: 2016
  end-page: 424
  ident: bib0090
  article-title: A qualitative exploration of perceived gender differences in methamphetamine use among women who use methamphetamine on the Mexico-U.S. border
  publication-title: J. Ethn. Subst. Abuse
– volume: 71
  start-page: 821
  year: 2014
  end-page: 826
  ident: bib0040
  article-title: The changing face of heroin use in the United States: a retrospective analysis of the past 50 years
  publication-title: JAMA Psychiatry
– volume: 372
  start-page: 241
  year: 2015
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0060
  article-title: Supplementary Appendix: trends in opioid analgesic abuse and mortality in the United States
  publication-title: N. Eng. J. Med.
  doi: 10.1056/NEJMsa1406143
– volume: 30
  start-page: 264
  year: 2011
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0095
  article-title: The prescription drug epidemic in the United States: a perfect storm
  publication-title: Drug Alcohol Rev.
  doi: 10.1111/j.1465-3362.2011.00291.x
– volume: 66
  start-page: 697
  year: 2017
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0070
  article-title: Vital signs: changes in opioid prescribing in the United States, 2006–2015
  publication-title: MMWR Morb. Mortal. Wkly. Rep.
  doi: 10.15585/mmwr.mm6626a4
– year: 2018
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0120
– year: 2018
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0110
– volume: 322
  start-page: 164
  year: 2016
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0115
  article-title: Differential activation of dopaminergic systems in rat brain basal ganglia by morphine and methamphetamine
  publication-title: Neuroscience
  doi: 10.1016/j.neuroscience.2016.01.043
– volume: 374
  start-page: 154
  year: 2016
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0050
  article-title: Relationship between nonmedical prescription-opioid use and heroin use
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMra1508490
– volume: 372
  start-page: 241
  year: 2015
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0055
  article-title: Trends in opioid analgesic abuse and mortality in the United States
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMsa1406143
– volume: 34
  start-page: e1
  year: 2016
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0160
  article-title: The opioid epidemic in the United States
  publication-title: Emerg. Med. Clin. North Am.
  doi: 10.1016/j.emc.2015.11.002
– volume: 374
  start-page: 301
  year: 2016
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0005
  article-title: Opioid prescribing for chronic pain—achieving the right balance through education
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMp1512932
– year: 2004
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0025
  article-title: Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction
– volume: 67
  start-page: 349
  year: 2018
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0140
  article-title: Overdose deaths involving opioids, cocaine, and psychostimulants – United States, 2015–2016
  publication-title: MMWR Morb. Mortal. Wkly. Rep.
  doi: 10.15585/mmwr.mm6712a1
– volume: 138
  start-page: 112
  year: 2018
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0065
  article-title: The opioid epidemic is an historic opportunity to improve both prevention and treatment
  publication-title: Brain Res. Bull.
  doi: 10.1016/j.brainresbull.2017.06.008
– volume: 129
  start-page: 139
  year: 2014
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0010
  article-title: Prescription drug monitoring and dispensing of prescription opioids
  publication-title: Public Health Rep.
  doi: 10.1177/003335491412900207
– volume: 173
  start-page: S4
  year: 2017
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0045
  article-title: Understanding the demand side of the prescription opioid epidemic: does the initial source of opioids matter?
  publication-title: Drug Alcohol Depend.
  doi: 10.1016/j.drugalcdep.2016.03.014
– volume: 31
  start-page: 112
  year: 2018
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0080
  article-title: Current state of vaccines in psychiatry—a narrative review
  publication-title: Asian J. Psychiatry
  doi: 10.1016/j.ajp.2018.02.004
– volume: 139
  start-page: 8601
  year: 2017
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0015
  article-title: Development of a clinically viable heroin vaccine
  publication-title: J. Am. Chem. Soc.
  doi: 10.1021/jacs.7b03334
– year: 2017
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0085
– year: 2018
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0150
– volume: 19
  start-page: 5
  year: 2018
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0130
  article-title: Vaccines to combat the opioid crisis. Vaccines that prevent opioids and other substances of abuse from entering the brain could effectively treat addiction and abuse
  publication-title: EMBO Rep.
  doi: 10.15252/embr.201745322
– volume: 66
  start-page: 1197
  year: 2017
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0125
  article-title: Deaths involving fentanyl, fentanyl analogs, and U-47700-10 States, July–December 2016
  publication-title: MMWR Morb. Mortal. Wkly. Rep.
  doi: 10.15585/mmwr.mm6643e1
– year: 2009
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0075
– volume: 48
  start-page: 1
  year: 2015
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0100
  article-title: Prescription drug abuse: from epidemiology to public policy
  publication-title: J. Subst. Abuse Treat.
  doi: 10.1016/j.jsat.2014.08.004
– volume: 125
  start-page: 1675
  year: 2017
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0145
  article-title: The US opioid crisis: current federal and state legal issues
  publication-title: Anesth. Analg.
  doi: 10.1213/ANE.0000000000002403
– volume: 15
  start-page: 405
  year: 2016
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0090
  article-title: A qualitative exploration of perceived gender differences in methamphetamine use among women who use methamphetamine on the Mexico-U.S. border
  publication-title: J. Ethn. Subst. Abuse
  doi: 10.1080/15332640.2015.1070392
– year: 2018
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0135
– volume: 8
  start-page: 157
  year: 2007
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0035
  article-title: The development of a comprehensive risk-management program for prescription opioid analgesics: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®)
  publication-title: Pain Med.
  doi: 10.1111/j.1526-4637.2006.00259.x
– year: 2017
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0155
– volume: 71
  start-page: 821
  year: 2014
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0040
  article-title: The changing face of heroin use in the United States: a retrospective analysis of the past 50 years
  publication-title: JAMA Psychiatry
  doi: 10.1001/jamapsychiatry.2014.366
– year: 2015
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0020
– volume: 72
  start-page: 424
  year: 2015
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0030
  article-title: Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from OxyContin
  publication-title: JAMA Psychiatry
  doi: 10.1001/jamapsychiatry.2014.3043
– volume: 77
  start-page: 774
  year: 2016
  ident: 10.1016/j.drugalcdep.2018.08.029_bib0105
  article-title: Prevalence and correlates of heroin-methamphetamine co-injection among persons who inject drugs in San Diego, California, and Tijuana, Baja California, Mexico
  publication-title: J. Stud. Alcohol Drugs
  doi: 10.15288/jsad.2016.77.774
SSID ssj0000690
Score 2.6490211
Snippet •Co-occurring opioid and methamphetamine use have doubled from 2011 to 2017.•Methamphetamine serves as an easily accessible and affordable substitute to...
Recent supply-side efforts enacted to curb the opioid epidemic have had both positive (i.e., prescription opioid abuse is on the decline) and negative outcomes...
Background/aims: Recent supply-side efforts enacted to curb the opioid epidemic have had both positive (i.e., prescription opioid abuse is on the decline) and...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 14
SubjectTerms Drug abuse
Drug addiction
Drug use
Epidemics
Help seeking behavior
Medical treatment
Methamphetamine
Narcotics
Opioids
Patients
Polls & surveys
Polysubstance use
Qualitative analysis
Rural communities
Rural populations
Substance abuse treatment
Treatment programs
Title Twin epidemics: The surging rise of methamphetamine use in chronic opioid users
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0376871618306872
https://dx.doi.org/10.1016/j.drugalcdep.2018.08.029
https://www.ncbi.nlm.nih.gov/pubmed/30326396
https://www.proquest.com/docview/2157473131
https://www.proquest.com/docview/2121487121
Volume 193
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dT9swELcQe-EFsY1Btw55EuIta504abw9ITTUDQ0eBoI3y5dcpUCXVGkj3vjbdxcn3SZtUiVeosTxWYl9H79LzndCHAOQH2GQJM0oE5DFgwDIDQtcErk0gjjF9g_-98tkeqO_3cV3W-Ks3wvDYZWd7vc6vdXWXcuom83RoihGP8YkGwz3iSnHdMJ6WOsJc_nHJ_WHNvbfWahzwL27aB4f45XXDenhLEfOXKnSNplnCzb_aaL-B0FbU3S-J3Y7DClP_WO-FFtYvhJDv9FW3uJ85mqUJ7JvqOqH1-Lq-rEoJfp6sNnykyT-kMum5hpFkgQdZTWTXE7a0fLiyv0k9CkbaiaqzCfQldWiqIqcW-vlvrg5_3J9Ng26YgpBpmOzCoCgWQioU1AuH2cJQ7uEBJpuKpeBNoBqFjlaGjLiMSe6AwOTNJkhOc8aTfRGbJdViYe8zRtAaRjnkaaxVQhJjMgjYqg5Qd5ATPr5s1mXaZwLXsxtH1J2b3_PvOWZt1wLMzQDodaUC59tYwMa0y-R7XeTkv6zZBI2oP28pv2L6zakHvYcYTvJX1qCUOShRSpSA_FhfZtkln_EuBKrhvuE5IVO6DgQB56T1q9LkILWxSRvn_Vo78QOX_m4m6HYXtUNvif0tIKjVjyOxIvTrxfTy1_xBxiq
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaqcigXBC2PhaUYCXELu06cbNyeUEW1fR_Yit4sTzIrpZRkld2IG7-dmThZigTSSr1Eke2JHHse3yTjGSE-AJAfYZAkzSgTkMWDAMgNC1wSuTSCOMX2D_7FZTK91qc38c2WOOrPwnBYZaf7vU5vtXXXMupWc7QoitHXMckGw31iyjHdkB5-pEl8uYzBp1_qnjr2H1podMDDu3AeH-SV1w0p4ixHTl2p0jabZ4s2_2mj_odBW1t0_FQ86UCk_Ozn-UxsYbkrhv6krfyGd3NXo_wo-4aq_r4nrmY_i1KiLwibLQ8kMYhcNjUXKZIk6SirueR60o72F1fuB8FP2VAzUWU-g66sFkVV5NxaL5-L6-Mvs6Np0FVTCDIdm1UAhM1CQJ2Ccvk4SxjbJSTR1KlcBtoAqnnkaG_Iisec6Q4MTNJkjuQ9azTRC7FdViW-4nPeAErDOI80PVuFkMSI_EQMNWfIG4hJv34261KNc8WLO9vHlN3aPytveeUtF8MMzUCoNeXCp9vYgMb0W2T746SkAC3ZhA1oD9e0f7HdhtTDniNsJ_pLSxiKXLRIRWog3q-7SWj5T4wrsWp4TEhu6ISuA_HSc9L6dQlT0L6Y5PWDpvZO7ExnF-f2_OTy7I14zD0-CGcotld1g28JSq1gvxWV3yx4Gjg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Twin+epidemics%3A+The+surging+rise+of+methamphetamine+use+in+chronic+opioid+users&rft.jtitle=Drug+and+alcohol+dependence&rft.au=Ellis%2C+Matthew+S.&rft.au=Kasper%2C+Zachary+A.&rft.au=Cicero%2C+Theodore+J.&rft.date=2018-12-01&rft.pub=Elsevier+B.V&rft.issn=0376-8716&rft.volume=193&rft.spage=14&rft.epage=20&rft_id=info:doi/10.1016%2Fj.drugalcdep.2018.08.029&rft.externalDocID=S0376871618306872
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0376-8716&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0376-8716&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0376-8716&client=summon